GNCA stock forecast
Our latest prediction for Genocea Biosciences, Inc.'s stock price was made on the June 24, 2019 when the stock price was at 3.65$.
In the short term (2weeks), GNCA's stock price should outperform the market by 5.32%. During that period the price should oscillate between -9.87% and +27.12%.
In the medium term (3months), GNCA's stock price should outperform the market by 4.83%. During that period the price should oscillate between -21.88% and +52.88%.Get email alerts
About Genocea Biosciences, Inc.
Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.16$ per share.
The book value per share is 0.15$
Three months stock forecastJune 24, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|